255 related articles for article (PubMed ID: 31376155)
1. Metabotropic glutamate receptor 5 (mGlu
Hellyer SD; Albold S; Sengmany K; Singh J; Leach K; Gregory KJ
J Neurochem; 2019 Nov; 151(3):301-315. PubMed ID: 31376155
[TBL] [Abstract][Full Text] [Related]
2. Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Tool Compounds to Study Signaling Bias.
Arsova A; Møller TC; Hellyer SD; Vedel L; Foster SR; Hansen JL; Bräuner-Osborne H; Gregory KJ
Mol Pharmacol; 2021 May; 99(5):328-341. PubMed ID: 33602724
[TBL] [Abstract][Full Text] [Related]
3. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
[TBL] [Abstract][Full Text] [Related]
4. Probe dependence and biased potentiation of metabotropic glutamate receptor 5 is mediated by differential ligand interactions in the common allosteric binding site.
Hellyer SD; Sengmany K; Keller AN; Christopoulos A; Leach K; Gregory KJ
Biochem Pharmacol; 2020 Jul; 177():114013. PubMed ID: 32389635
[TBL] [Abstract][Full Text] [Related]
5. Differential contribution of metabotropic glutamate receptor 5 common allosteric binding site residues to biased allosteric agonism.
Sengmany K; Hellyer SD; Christopoulos A; Lapinsky DJ; Leach K; Gregory KJ
Biochem Pharmacol; 2020 Jul; 177():114011. PubMed ID: 32380090
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding.
Butkiewicz M; Rodriguez AL; Rainey SE; Wieting J; Luscombe VB; Stauffer SR; Lindsley CW; Conn PJ; Meiler J
ACS Chem Neurosci; 2019 Aug; 10(8):3427-3436. PubMed ID: 31132237
[TBL] [Abstract][Full Text] [Related]
7. Effects of positive allosteric modulators on single-cell oscillatory Ca2+ signaling initiated by the type 5 metabotropic glutamate receptor.
Bradley SJ; Watson JM; Challiss RA
Mol Pharmacol; 2009 Dec; 76(6):1302-13. PubMed ID: 19737913
[TBL] [Abstract][Full Text] [Related]
8. Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.
Sengmany K; Hellyer SD; Albold S; Wang T; Conn PJ; May LT; Christopoulos A; Leach K; Gregory KJ
Neuropharmacology; 2019 May; 149():83-96. PubMed ID: 30763654
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration.
Parmentier-Batteur S; O'Brien JA; Doran S; Nguyen SJ; Flick RB; Uslaner JM; Chen H; Finger EN; Williams TM; Jacobson MA; Hutson PH
Neuropharmacology; 2012 Mar; 62(3):1453-60. PubMed ID: 21112344
[TBL] [Abstract][Full Text] [Related]
10. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).
Turlington M; Noetzel MJ; Chun A; Zhou Y; Gogliotti RD; Nguyen ED; Gregory KJ; Vinson PN; Rook JM; Gogi KK; Xiang Z; Bridges TM; Daniels JS; Jones C; Niswender CM; Meiler J; Conn PJ; Lindsley CW; Stauffer SR
J Med Chem; 2013 Oct; 56(20):7976-96. PubMed ID: 24050755
[TBL] [Abstract][Full Text] [Related]
11. Development of allosteric modulators of GPCRs for treatment of CNS disorders.
Nickols HH; Conn PJ
Neurobiol Dis; 2014 Jan; 61():55-71. PubMed ID: 24076101
[TBL] [Abstract][Full Text] [Related]
12. Striatal and cortical metabotropic glutamate 5 receptor expression and behavioral effects of the positive allosteric modulator CDPPB in a model of DYT1 dystonia.
Perl S; Richter F; Richter A
Pharmacol Biochem Behav; 2020 Sep; 196():172977. PubMed ID: 32615137
[TBL] [Abstract][Full Text] [Related]
13. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.
Rook JM; Noetzel MJ; Pouliot WA; Bridges TM; Vinson PN; Cho HP; Zhou Y; Gogliotti RD; Manka JT; Gregory KJ; Stauffer SR; Dudek FE; Xiang Z; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
Biol Psychiatry; 2013 Mar; 73(6):501-9. PubMed ID: 23140665
[TBL] [Abstract][Full Text] [Related]
14. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
Parmentier-Batteur S; Hutson PH; Menzel K; Uslaner JM; Mattson BA; O'Brien JA; Magliaro BC; Forest T; Stump CA; Tynebor RM; Anthony NJ; Tucker TJ; Zhang XF; Gomez R; Huszar SL; Lambeng N; Fauré H; Le Poul E; Poli S; Rosahl TW; Rocher JP; Hargreaves R; Williams TM
Neuropharmacology; 2014 Jul; 82():161-73. PubMed ID: 23291536
[TBL] [Abstract][Full Text] [Related]
15. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles.
Rook JM; Tantawy MN; Ansari MS; Felts AS; Stauffer SR; Emmitte KA; Kessler RM; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
Neuropsychopharmacology; 2015 Feb; 40(3):755-65. PubMed ID: 25241804
[TBL] [Abstract][Full Text] [Related]
16. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy.
Nickols HH; Yuh JP; Gregory KJ; Morrison RD; Bates BS; Stauffer SR; Emmitte KA; Bubser M; Peng W; Nedelcovych MT; Thompson A; Lv X; Xiang Z; Daniels JS; Niswender CM; Lindsley CW; Jones CK; Conn PJ
J Pharmacol Exp Ther; 2016 Jan; 356(1):123-36. PubMed ID: 26503377
[TBL] [Abstract][Full Text] [Related]
17. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators.
Rodriguez AL; Nong Y; Sekaran NK; Alagille D; Tamagnan GD; Conn PJ
Mol Pharmacol; 2005 Dec; 68(6):1793-802. PubMed ID: 16155210
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia.
Bradley SJ; Langmead CJ; Watson JM; Challiss RA
Mol Pharmacol; 2011 May; 79(5):874-85. PubMed ID: 21321061
[TBL] [Abstract][Full Text] [Related]
19. "Selective" Class C G Protein-Coupled Receptor Modulators Are Neutral or Biased mGlu
Hellyer SD; Albold S; Wang T; Chen ANY; May LT; Leach K; Gregory KJ
Mol Pharmacol; 2018 May; 93(5):504-514. PubMed ID: 29514854
[TBL] [Abstract][Full Text] [Related]
20. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling.
Noetzel MJ; Gregory KJ; Vinson PN; Manka JT; Stauffer SR; Lindsley CW; Niswender CM; Xiang Z; Conn PJ
Mol Pharmacol; 2013 Apr; 83(4):835-47. PubMed ID: 23348500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
